FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2615393916> ?p ?o ?g. }

• W2615393916 endingPage "1296" @default.
• W2615393916 startingPage "1288" @default.
• W2615393916 abstract "Abstract BACKGROUND Circulating cell-free DNA methylation testing in blood has recently received regulatory approval for screening of colorectal cancer. Its application in other clinical settings, including staging, prognosis, prediction, and recurrence monitoring is highly promising, and of particular interest in head and neck squamous cell carcinomas (HNSCCs) that represent a heterogeneous group of cancers with unsatisfactory treatment guidelines. METHODS Short stature homeobox 2 (SHOX2) and septin 9 (SEPT9) DNA methylation in plasma from 649 prospectively enrolled patients (training study: 284 HNSCC/122 control patients; testing study: 141 HNSCC/102 control patients) was quantified before treatment and longitudinally during surveillance. RESULTS In the training study, 59% of HNSCC patients were methylation-positive at 96% specificity. Methylation levels correlated with tumor and nodal category (P &lt; 0.001). Initially increased methylation levels were associated with a higher risk of death [SEPT9: hazard ratio (HR) = 5.27, P = 0.001; SHOX2: HR = 2.32, P = 0.024]. Disease recurrence/metastases were detected in 47% of patients up to 377 days earlier compared to current clinical practice. The onset of second cancers was detected up to 343 days earlier. In the testing study, sensitivity (52%), specificity (95%), prediction of overall survival (SEPT9: HR = 2.78, P = 0.022; SHOX2: HR = 2.50, P = 0.026), and correlation with tumor and nodal category (P &lt;0.001) were successfully validated. CONCLUSIONS Methylation testing in plasma is a powerful diagnostic tool for molecular disease staging, risk stratification, and disease monitoring. Patients with initially high biomarker levels might benefit from intensified treatment and posttherapeutic surveillance. The early detection of a recurrent/metastatic disease or a second malignancy could lead to an earlier consecutive treatment, thereby improving patients' outcomes." @default.
• W2615393916 created "2017-05-26" @default.
• W2615393916 creator A5000038661 @default.
• W2615393916 creator A5006756515 @default.
• W2615393916 creator A5007871038 @default.
• W2615393916 creator A5012229709 @default.
• W2615393916 creator A5017462100 @default.
• W2615393916 creator A5025079546 @default.
• W2615393916 creator A5027763124 @default.
• W2615393916 creator A5033446747 @default.
• W2615393916 creator A5034359692 @default.
• W2615393916 creator A5035645017 @default.
• W2615393916 creator A5036274083 @default.
• W2615393916 creator A5038996741 @default.
• W2615393916 creator A5041337624 @default.
• W2615393916 creator A5046234297 @default.
• W2615393916 creator A5057868980 @default.
• W2615393916 creator A5070273513 @default.
• W2615393916 creator A5077502588 @default.
• W2615393916 creator A5088527060 @default.
• W2615393916 date "2017-07-01" @default.
• W2615393916 modified "2023-09-30" @default.
• W2615393916 title "Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study" @default.
• W2615393916 cites W1534396615 @default.
• W2615393916 cites W1535136055 @default.
• W2615393916 cites W1571418278 @default.
• W2615393916 cites W1823658262 @default.
• W2615393916 cites W1978889425 @default.
• W2615393916 cites W1982857584 @default.
• W2615393916 cites W1991581123 @default.
• W2615393916 cites W1994290735 @default.
• W2615393916 cites W1996628512 @default.
• W2615393916 cites W2003097348 @default.
• W2615393916 cites W2003643844 @default.
• W2615393916 cites W2025355337 @default.
• W2615393916 cites W2027433423 @default.
• W2615393916 cites W2036005555 @default.
• W2615393916 cites W2051532990 @default.
• W2615393916 cites W2064498697 @default.
• W2615393916 cites W2064779735 @default.
• W2615393916 cites W2074299339 @default.
• W2615393916 cites W2079173253 @default.
• W2615393916 cites W2089135124 @default.
• W2615393916 cites W2097308306 @default.
• W2615393916 cites W2118991777 @default.
• W2615393916 cites W2121614062 @default.
• W2615393916 cites W2127821100 @default.
• W2615393916 cites W2134383694 @default.
• W2615393916 cites W2135672265 @default.
• W2615393916 cites W2168133848 @default.
• W2615393916 cites W2289883858 @default.
• W2615393916 cites W2510474544 @default.
• W2615393916 cites W2522622119 @default.
• W2615393916 cites W2567180171 @default.
• W2615393916 doi "https://doi.org/10.1373/clinchem.2016.270207" @default.
• W2615393916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28515105" @default.
• W2615393916 hasPublicationYear "2017" @default.
• W2615393916 type Work @default.
• W2615393916 sameAs 2615393916 @default.
• W2615393916 citedByCount "84" @default.
• W2615393916 countsByYear W26153939162017 @default.
• W2615393916 countsByYear W26153939162018 @default.
• W2615393916 countsByYear W26153939162019 @default.
• W2615393916 countsByYear W26153939162020 @default.
• W2615393916 countsByYear W26153939162021 @default.
• W2615393916 countsByYear W26153939162022 @default.
• W2615393916 countsByYear W26153939162023 @default.
• W2615393916 crossrefType "journal-article" @default.
• W2615393916 hasAuthorship W2615393916A5000038661 @default.
• W2615393916 hasAuthorship W2615393916A5006756515 @default.
• W2615393916 hasAuthorship W2615393916A5007871038 @default.
• W2615393916 hasAuthorship W2615393916A5012229709 @default.
• W2615393916 hasAuthorship W2615393916A5017462100 @default.
• W2615393916 hasAuthorship W2615393916A5025079546 @default.
• W2615393916 hasAuthorship W2615393916A5027763124 @default.
• W2615393916 hasAuthorship W2615393916A5033446747 @default.
• W2615393916 hasAuthorship W2615393916A5034359692 @default.
• W2615393916 hasAuthorship W2615393916A5035645017 @default.
• W2615393916 hasAuthorship W2615393916A5036274083 @default.
• W2615393916 hasAuthorship W2615393916A5038996741 @default.
• W2615393916 hasAuthorship W2615393916A5041337624 @default.
• W2615393916 hasAuthorship W2615393916A5046234297 @default.
• W2615393916 hasAuthorship W2615393916A5057868980 @default.
• W2615393916 hasAuthorship W2615393916A5070273513 @default.
• W2615393916 hasAuthorship W2615393916A5077502588 @default.
• W2615393916 hasAuthorship W2615393916A5088527060 @default.
• W2615393916 hasBestOaLocation W26153939161 @default.
• W2615393916 hasConcept C104317684 @default.
• W2615393916 hasConcept C121608353 @default.
• W2615393916 hasConcept C126322002 @default.
• W2615393916 hasConcept C143998085 @default.
• W2615393916 hasConcept C150194340 @default.
• W2615393916 hasConcept C185592680 @default.
• W2615393916 hasConcept C188816634 @default.
• W2615393916 hasConcept C190727270 @default.
• W2615393916 hasConcept C207103383 @default.
• W2615393916 hasConcept C2776530083 @default.
• W2615393916 hasConcept C2776833033 @default.

• next